Crispr Therapeutics (CRSP) won its second gene-editing approval on Tuesday — two months ahead of expectations. But CRSP stock slipped at the close. X The Food and Drug Administration signed off on Crispr’s drug, Casgevy, for patients age 12 and older with beta thalassemia. Crispr developed Casgevy with Vertex Pharmaceuticals (VRTX). Beta thalassemia is an […]
With the launch of its first gene therapy that’s near-curative for sickle cell disease (SCD), everyone’s talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals. But CRISPR isn’t the only biotech pursuing advanced medicines, and investors are already looking for the next players that might make big breakthroughs. It’s riskier to invest […]
Scientists studying DNA. December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR’s gene-editing therapy, Casgevy, as a treatment for sickle cell disease. It was a monumental decision as it also marked the first approval for a therapy utilizing the CRISPR/Cas9 […]